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Dear Editor,
We are reporting five recommendations related to tests, treat-
ments, and procedures at risk of inappropriateness in the cure
of Parkinson’s disease. These recommendations were identi-
fied by the Academy for the Study of Parkinson’s Disease and
Movement Disorders (LIMPE-DISMOV Academy), in col-
laboration with Slow Medicine. Slow Medicine, an Italian
movement of health professionals, patients, and citizens pro-
moting a BMeasured, Respectful and Equitable Medicine^,
launched the campaign BDoing more does not mean doing
better- Choosing Wisely Italy^ in Italy at the end of 2012,
similar to Choosing Wisely in the USA. The campaign aims
to help physicians, other health professionals, patients, and
citizens engage in conversations about tests or procedures
commonly used in their field whose necessity should be
questioned and discussed. This call to action has resulted in
specialty-specific lists of BThings Providers and Patients
Should Question.^
The five recommendations related to Parkinson’s disease
were selected during a meeting of the board of the LIMPE-
DISMOV Academy on the basis of a list drawn up by the
individual members of the board. Each member of the board
has indicated a practice, commonly carried out in Italy, for
which there are well-founded reasons to consider possible its
inappropriate use, which does not bring significant benefits to
patients, but rather a greater incidence of side effects or inad-
equate care. In the selection process, the board of the LIMPE-
DISMOVAcademy took into careful consideration the level
of evidence of the practices that was recently revised in the
BLinea Guida Diagnosi e Terapia della Malattia di Parkinson^
published in 2013 and updated in 2015, drafted by LIMPE in
collaboration with the Istituto Superiore di Sanità.
1. Do not use the brain single photon emission tomography
with tracers for dopaminergic transporters (DAT-SPECT)
for the prognosis and to ascertain the progression of
Parkinson’s disease.
The DaTscan, a dopamine transporter (DAT) single photon
emission computerized tomography (SPECT) imaging tech-
nique, proved to be valid in the differential diagnosis between
Parkinson’s disease and selected neurological conditions (es-
sential tremor, dystonic tremor, and psychogenic parkinson-
ism). However, several studies have shown that there is insuf-
ficient evidence to support the use of DaTscan as a prognostic
factor or as a measure of disease progression in Parkinson’s
disease [1].
2. Do not use antipsychotic medication except clozapine and
quetiapine to treat psychosis in Parkinson’s disease.
Several studies have shown that clozapine and quetiapine,
when used to treat psychosis in Parkinson’s disease do not
worsen motor symptoms, unlike other antipsychotics. In pa-
tients with psychosis and Parkinson’s disease, treatment with
low-dose clozapine should be considered as the first choice in
the treatment of psychosis. However, a mandatory require-
ment for clozapine use is regular monitoring of white blood
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cell count and absolute neutrophil count. If regular weekly
blood tests are not possible, low-dose quetiapine should be
considered as an alternative antipsychotic therapy for the treat-
ment of psychosis in Parkinson’s disease [2].
3. Do not delay prescribing Levodopa therapy to treat pa-
tients early in the course of Parkinson’s disease.
Prescription of levodopa as a pharmacological treatment
for Parkinson’s disease is often delayed in favor of
levodopa-sparing therapies (such as dopamine agonists) due
to concerns regarding the risk of drug-induced motor compli-
cations or possible toxic effect of levodopa. However, the
increase in the risk of motor complications associated to levo-
dopa therapy compared to dopamine agonist therapy is still
debated, while several studies showed that the use of dopa-
mine agonists increases the incidence of other important side
effects (such as impulse control disorders) and induces scarcer
control of motor symptoms compared to levodopa.
Furthermore, clinical studies have not brought conclusive ev-
idence on the risk of neurotoxicity by early treatment with
levodopa. Patients in the early stage of Parkinson’s disease
may be considered for treatment with levodopa if required
by the clinical condition. Noteworthy, the combined treatment
of levodopa and entacapone in the early stage of the disease is
not indicated, in order to reduce the risk of motor complica-
tions [3].
4. Do not use myocardial scintigraphy with metaiodobenzyl
guanidine (MIBG) to diagnose Parkinson’s disease.
[123I]-MIBG myocardial scintigraphy was originally de-
veloped to assess postganglionic presynaptic cardiac sympa-
thetic nerve endings in heart disease. Subsequently, cardiac
MIBG uptake was demonstrated to be reduced in patients with
Lewy body diseases such as Parkinson’s disease. However,
several studies have shown that the sensitivity of MIBG myo-
cardial scintigraphy is comparable to that of clinical diagnosis.
Therefore, cardiac [123I]-MIBGmyocardial scintigraphymay
assist in the differential diagnosis of Parkinson’s disease ver-
sus other parkinsonisms, but it must not be used not to replace
clinical diagnosis, especially in the early stages of the disease
or in the case of diagnostic uncertainty. Furthermore, particu-
lar attention should be paid to the pharmacological treatments
of patients, in particular tricyclic antidepressants, which can
interfere with the result of the [123I]-MIBG myocardial scin-
tigraphy [4].
5. Do not use anticholinergic drugs to treat the motor symp-
toms of drug-induced parkinsonisms.
Although anticholinergic drugs have been widely used in
the control of parkinsonian symptoms in Parkinson’s disease
and in parkinsonisms (including drug-induced parkinsonism),
the current evidence shows that such drugs have a limited
benefit on tremor and are associated with cognitive and neu-
ropsychiatric side effects.
Thus, the use of anticholinergics should be limited in pa-
tients with comorbidities as cognitive impairment or clinically
significant psychiatric illness. Furthermore, the use of anticho-
linergic drugs is not recommended for the treatment of motor
symptoms in drug-induced parkinsonisms [5].
Conclusions
The mission of Choosing Wisely is to promote conversations
between clinicians and patients by helping patients to choose
care that is supported by evidence, not duplicative of other
tests or procedures already received, free from harm and truly
necessary. The LIMPE-DISMOVAcademy as national socie-
ty with the mission of fighting against Parkinson’s disease and
of promoting strong interactions between patients and clini-
cians decided to join with enthusiasm the Choosing Wisely
campaign in the hope that the recognition of evidence-based
recommendations regarding low-value services in our special-
ty reduce unnecessary care, avoid harm, and decrease waste.
Future studies will verify if targeting these low-value ser-
vices and implementing Choosing Wisely recommendations
related to tests, treatments, and procedures at risk of inappro-
priateness in the cure of Parkinson’s disease will achieve the
expected positive results.
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